Acurx Pharmaceuticals, Inc. (ACXP)
Score window: Apr. 15, 2025 to Apr. 14, 2026
| Date | Form | Sentiment | Urgency | Summary | Open |
|---|---|---|---|---|---|
| Jan. 2, 2026 | CORRESP | Neutral/Informational | Moderate | Acurx Pharmaceuticals, Inc. submitted a request to the SEC to accelerate the effective date of their Registration Statement on Form S-3, originally filed on July 9, 2025. They are… | Read Filing EDGAR |
| Jul. 21, 2025 | CORRESP | Neutral/Informational | Moderate | Acurx Pharmaceuticals, Inc. has submitted a request for acceleration of the effective date of its Registration Statement on Form S-1, seeking to have it become effective on July 2… | Read Filing EDGAR |
| Jul. 21, 2025 | UPLOAD | Neutral/Informational | Low | The SEC correspondence dated July 21, 2025, informs Acurx Pharmaceuticals, Inc. that their registration statement on Form S-1, filed on July 15, 2025, has not been reviewed and wi… | Read Filing EDGAR |
| Jul. 14, 2025 | UPLOAD | Neutral/Informational | Low | The SEC has communicated to Acurx Pharmaceuticals, Inc. that they will not review the company's registration statement filed on July 9, 2025. The letter emphasizes the company's r… | Read Filing EDGAR |
| May. 27, 2025 | CORRESP | Neutral/Informational | Moderate | Acurx Pharmaceuticals, Inc. has submitted a request for the acceleration of the effective date of its Registration Statement on Form S-1. The company aims for the registration to … | Read Filing EDGAR |
| May. 27, 2025 | UPLOAD | Neutral/Informational | Low | The SEC correspondence addressed to David Luci, CEO of Acurx Pharmaceuticals, Inc., informs the company that their registration statement on Form S-1, filed on May 21, 2025, will … | Read Filing EDGAR |